12:00 AM
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Bexsero: Phase III data

Last November, EMA's CHMP issued a positive opinion recommending approval of Bexsero to vaccinate against meningococcal disease caused by Neisseria meningitides group B in individuals aged 2 months and older (see BioCentury, Nov. 19, 2012).

Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland
Product: Bexsero
Business: Infectious
Molecular target: NA
Description: Multi-component meningococcal serogroup B vaccine

Read the full 267 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >